

# Amit M Oza

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6946256/amit-m-oza-publications-by-citations.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

191  
papers

17,160  
citations

52  
h-index

130  
g-index

198  
ext. papers

21,415  
ext. citations

9  
avg, IF

6.41  
L-index

#	Paper	IF	Citations
191	A phase 3 trial of bevacizumab in ovarian cancer. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2484-96	59.2	1454
190	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2154-2164	59.2	1259
189	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2495-2505	59.2	1061
188	Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. <i>Lancet, The</i> , <b>2014</b> , 383, 1721-30	40	1015
187	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1274-1284	21.7	913
186	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , <b>2011</b> , 11, 719-25	31.3	893
185	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 852-61	21.7	883
184	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 390, 1949-1961	40	815
183	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 75-87	21.7	706
182	Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2059-69	2.2	548
181	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 928-36	21.7	475
180	Epithelial ovarian cancer. <i>Lancet, The</i> , <b>2019</b> , 393, 1240-1253	40	463
179	Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 76-82	2.2	462
178	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 87-97	21.7	405
177	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2019</b> , 69, 280-304	220.7	292
176	Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3278-85	2.2	274
175	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 799-808	21.7	238

174	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 636-648	21.7	215
173	Secondary Somatic Mutations Restoring and Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , <b>2017</b> , 7, 984-998	24.4	193
172	A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline -Mutated Ovarian Carcinoma or Other Solid Tumors. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4095-4106	12.9	164
171	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , <b>2017</b> , 147, 267-275	4.9	163
170	Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1266-74	2.2	152
169	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , <b>2016</b> , 8, 109	14.4	149
168	Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , <b>2019</b> , 9, 210-219	24.4	142
167	Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4371-4380	2.2	132
166	Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4319-25	2.2	115
165	Outcomes and endpoints in trials of cancer treatment: the past, present, and future. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e32-42	21.7	111
164	Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 236-43	21.7	105
163	Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5485-93	12.9	103
162	Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. <i>Cancer</i> , <b>2007</b> , 109, 692-702	6.4	102
161	Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1574-82	12.9	101
160	Treatment strategies for endometrial cancer: current practice and perspective. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2017</b> , 29, 47-58	2.4	96
159	Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. <i>Cancer</i> , <b>2014</b> , 120, 3932-9	6.4	87
158	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4086-4094	12.9	83
157	A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. <i>Gynecologic Oncology</i> , <b>2010</b> , 117, 37-40	4.9	77

156	Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3576-82	2.2	74
155	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. <i>JAMA Oncology</i> , <b>2018</b> , 4, e173776	13.4	72
154	Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. <i>Gynecologic Oncology</i> , <b>2014</b> , 135, 184-9	4.9	69
153	A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2013</b> , 130, 25-30	4.9	68
152	Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). <i>European Journal of Cancer</i> , <b>2010</b> , 46, 1365-73	7.5	66
151	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 1117-1125	21.7	65
150	Gynecologic Cancer InterGroup (GCIg) consensus review for mucinous ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, S14-9	3.5	64
149	Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. <i>Gynecologic Oncology</i> , <b>2016</b> , 143, 27-34	4.9	63
148	Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1240-1249	2.2	59
147	Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. <i>Oncotarget</i> , <b>2015</b> , 4, e1026529	7.2	59
146	Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , <b>2017</b> , 145, 584-594	4.9	58
145	Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. <i>Cancer</i> , <b>2014</b> , 120, 603-10	6.4	58
144	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. <i>European Journal of Cancer</i> , <b>2017</b> , 70, 111-121	7.5	57
143	Outcomes and endpoints in cancer trials: bridging the divide. <i>Lancet Oncology</i> , <b>2015</b> , 16, e43-52	21.7	56
142	The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4549-4558	12.9	55
141	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6002-6002	2.2	54
140	Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5508-5508	2.2	52
139	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , <b>2016</b> , 142, 62-69	4.9	51

138	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 862-876	21.7	48
137	A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 55-61	4.9	48
136	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. <i>Gynecologic Oncology</i> , <b>2015</b> , 137, 216-22	4.9	48
135	Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. <i>Investigational New Drugs</i> , <b>2016</b> , 34, 355-63	4.3	46
134	Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. <i>Genome Medicine</i> , <b>2018</b> , 10, 81	14.4	46
133	Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. <i>Cancer</i> , <b>2015</b> , 121, 1737-46	6.4	45
132	Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	45
131	A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. <i>Gynecologic Oncology</i> , <b>2014</b> , 134, 274-80	4.9	45
130	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1182-91	4.3	45
129	FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 1669-1678	3.6	43
128	Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 50-58	3.5	38
127	Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. <i>Cancer</i> , <b>2014</b> , 120, 335-43	6.4	38
126	Tailoring Ovarian Cancer Treatment: Implications of Mutations. <i>Cancers</i> , <b>2019</b> , 11,	6.6	34
125	Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 285-91	4.9	32
124	Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , <b>2021</b> , 397, 281-292	4.0	32
123	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6168-6174	12.9	30
122	EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4206-4215	12.9	30
121	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3528-3537	2.2	29

120	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive -mutant Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4767-4776	12.9	28
119	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 710-722	21.7	28
118	Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments. <i>European Journal of Cancer</i> , <b>2016</b> , 59, 99-108	7.5	28
117	ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 121-31	7.5	28
116	Ovarian cancer treatment: The end of empiricism?. <i>Cancer</i> , <b>2015</b> , 121, 3203-11	6.4	27
115	Better therapeutic trials in ovarian cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju029	9.7	27
114	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 53-60	4.9	26
113	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , <b>2021</b> , 12, 2487	17.4	24
112	mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , <b>2019</b> , 29, 346-352	3.5	21
111	Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 94, 111-117	4	21
110	A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 52-7	4.9	21
109	Niraparib for the treatment of ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 631-640	4	20
108	Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. <i>Gynecologic Oncology</i> , <b>2014</b> , 133, 460-6	4.9	18
107	QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received B prior chemotherapy regimens.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5514-5514	2.2	17
106	Updates and current challenges in microRNA research for personalized medicine in ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 927-943	5.4	15
105	Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 903-915	3.5	15
104	Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. <i>Gynecologic Oncology</i> , <b>2018</b> , 149, 275-282	4.9	15
103	The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 238-244	3.5	15

102	A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve. <i>Oncologist</i> , <b>2018</b> , 23, 203-213	5.7	15
101	Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. <i>Oncologist</i> , <b>2017</b> , 22, 1117-1124	5.7	14
100	COVID-19 Testing in Patients with Cancer: Does One Size Fit All?. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4737-4742	4.7	14
99	A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 83	8.5	14
98	Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective. <i>Obstetrics and Gynecology International</i> , <b>2018</b> , 2018, 1867238	2	14
97	Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1E17K mutation positive advanced solid tumors <b>2015</b> ,		14
96	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 632-642	21.7	14
95	The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). <i>Gynecologic Oncology</i> , <b>2013</b> , 130, 289-94	4.9	13
94	Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium. <i>Blood</i> , <b>2016</b> , 128, 4526-4526	2.2	13
93	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3494-3505	2.2	13
92	Safety evaluation of olaparib for treating ovarian cancer. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 1305-141	4.1	12
91	Additional germline findings from a tumor profiling program. <i>BMC Medical Genomics</i> , <b>2018</b> , 11, 65	3.7	12
90	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors <b>2020</b> , 8,		12
89	Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. <i>Frontiers in Oncology</i> , <b>2016</b> , 6, 119	5.3	12
88	High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. <i>Cancer</i> , <b>2019</b> , 125, 2772-2781	6.4	11
87	A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortium. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5510-5516	2.2	11
86	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, -mutated, high-grade ovarian cancer, and an update on safety. <i>International Journal of Gynecological Cancer</i> , <b>2019</b> , 29, 1396-1404	3.5	11
85	Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer. <i>Journal of Oncology Practice</i> , <b>2019</b> , 15, e1066-e1075	3.1	10

84	Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 90-4	4.9	10
83	Recent advances in systemic therapy for advanced endometrial cancer. <i>Current Opinion in Oncology</i> , <b>2011</b> , 23, 494-500	4.2	10
82	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 35, e247- <del>57</del> <sup>77</sup>	7.7	9
81	Advances in ovarian cancer, from biology to treatment.. <i>Nature Cancer</i> , <b>2021</b> , 2, 6-8	15.4	9
80	Targeting Angiogenesis: Taming the Medusa of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>2018</b> , 32, 1041-1055	3.1	9
79	Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.. <i>Lancet Oncology, The</i> , <b>2022</b> ,	21.7	9
78	Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2019</b> , 39, e152-e166	7.1	8
77	Olaparib for the treatment of ovarian cancer. <i>Expert Opinion on Orphan Drugs</i> , <b>2014</b> , 2, 497-508	1.1	8
76	Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5025-5025	2.2	7
75	Clinical data from the DeCideE1 trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5510-5510	2.2	7
74	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 101-111	4.9	7
73	Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 304-311	4.9	6
72	Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study. <i>Gynecologic Oncology</i> , <b>2020</b> , 157, 745-753	4.9	6
71	Current and emerging treatment options in the management of advanced ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 1063-76	4	6
70	New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?. <i>Current Oncology Reports</i> , <b>2016</b> , 18, 23	6.3	6
69	Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. <i>Expert Opinion on Orphan Drugs</i> , <b>2017</b> , 5, 71-83	1.1	6
68	Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 311-6	4.9	6
67	Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FR $\alpha$ )-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5547-5547	2.2	6



66	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 36, e247-e257	7.1	6
65	The role of niraparib for the treatment of ovarian cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 2565-2577	3.6	6
64	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 1589-1594	3.5	6
63	Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 523-525	12.9	5
62	Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer. <i>Cancer</i> , <b>2020</b> , 126, 4886-4894	6.4	5
61	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. <i>Cells</i> , <b>2019</b> , 8,	7.9	4
60	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2477-2486	12.9	4
59	A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. <i>Investigational New Drugs</i> , <b>2016</b> , 34, 231-5	4.3	4
58	Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 235-7	4.9	4
57	Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6068-6068	2.2	4
56	Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a -mutated low-grade serous ovarian cancer patient. <i>Journal of Physical Education and Sports Management</i> , <b>2019</b> , 5,	2.8	4
55	Advances in prediction for ovarian cancer treatment stratification. <i>Nature Reviews Clinical Oncology</i> , <b>2019</b> , 16, 75-76	19.4	4
54	Moving From Mutation to Actionability. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 495-503	7.1	4
53	Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa. <i>Modern Pathology</i> , <b>2020</b> , 33, 2361-2377	9.8	3
52	Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study. <i>Journal of Surgical Oncology</i> , <b>2019</b> , 120, 786-793	2.8	3
51	Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 124, 74-79	5.3	3
50	Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5518-5518	2.2	3
49	Feasibility and safety of front-line bevacizumab (BEV)-containing therapy after neoadjuvant (NA) chemotherapy (CT) for ovarian cancer (OC): The ROSiA experience.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5541-5541	2.2	3

48	Measuring Quality of Life in Ovarian Cancer Clinical Trials-Can We Improve Objectivity and Cross Trial Comparisons?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
47	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 539-545	4.9	3
46	DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1824-1828	3.5	3
45	Optimizing clinical research procedures in public health emergencies. <i>Medicinal Research Reviews</i> , <b>2021</b> , 41, 725-738	14.4	3
44	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 490-497	4.9	3
43	Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer. <i>Cancer</i> , <b>2015</b> , 121, 413-22	6.4	2
42	Targeting TGF $\beta$ Pathway in Adult Granulosa Cell Tumor: Opening Pandora's Box?. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5432-5434	12.9	2
41	Prospective evaluation of quality of life (QOL) during a phase I/II study of adjuvant chemotherapy with image-guided high-precision radiotherapy for completely resected gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 164-164	2.2	2
40	Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer. <i>Cancer</i> , <b>2021</b> , 127, 3082-3091	6.4	2
39	The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches. <i>Gynecologic Oncology</i> , <b>2021</b> , 162, 97-106	4.9	2
38	Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 139-143	3.5	2
37	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. <i>Cancer Medicine</i> , <b>2021</b> , 10, 7162-7173	4.8	2
36	Targeting the microenvironment in ovarian cancer. <i>Lancet Oncology</i> , <b>2015</b> , 16, 485-6	21.7	1
35	Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4432-4434	12.9	1
34	Emerging growth factor receptor antagonists for ovarian cancer treatment. <i>Expert Opinion on Emerging Drugs</i> , <b>2018</b> , 23, 1-16	3.7	1
33	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 96, 994-1002	4	1
32	Resisting RECIST-Uniformity Versus Clinical Validity. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 1619-1627	3.5	1
31	Discrepancies in drug approvals: A global dilemma. <i>Cancer</i> , <b>2015</b> , 121, 3360-1	6.4	1

30	Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3072-3072	2.2	1
29	Safety and efficacy of extended bevacizumab (BEV) therapy in elderly (≥70 years) patients (pts) treated for newly diagnosed ovarian cancer (OC) in the international ROSiA study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5535-5535	2.2	1
28	Immunologic and genomic characterization of high grade serous ovarian cancer (HGSOC) in patients (pts) treated with pembrolizumab (Pembro) in the phase II INSPIRE trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5581-5581	2.2	1
27	Targeted Therapy in Management of Endometrial Cancer <b>2020</b> , 249-276		1
26	Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1256-1257	3.5	1
25	Impact of an internal medicine nocturnist service on care of patients with cancer at a large Canadian teaching hospital: a quality-improvement study. <i>CMAJ Open</i> , <b>2021</b> , 9, E667-E672	2.5	1
24	SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS5610-TPS5610	2.2	1
23	Ethical frameworks in clinical research processes during COVID-19: a scoping review. <i>BMJ Open</i> , <b>2021</b> , 11, e047076	3	1
22	Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature. <i>Current Oncology</i> , <b>2021</b> , 28, 661-670	2.8	1
21	A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors. <i>Oncologist</i> , <b>2021</b> , 26, e2254-e2264	5.7	1
20	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , <b>2021</b> , 154, 190-200	7.5	1
19	Updates on systemic therapy for cervical cancer.. <i>Indian Journal of Medical Research</i> , <b>2021</b> , 154, 293-302	2.9	1
18	Conservative management of adnexal masses. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 326-327	21.7	0
17	Moving Beyond BRCA-Incorporating Molecular Assays into Ovarian Cancer Trials. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5271-5273	12.9	0
16	Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 221-227	4.9	0
15	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 949-958	3.5	0
14	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 668-675	4.9	0
13	Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 225, 658.e1-658.e9	6.4	0

12	Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer. <i>Cancer Research Communications</i> , <b>2022</b> , 2, 293-306	0
11	Rucaparib for the treatment of ovarian cancer. <i>Expert Opinion on Orphan Drugs</i> , <b>2018</b> , 6, 151-161	1.1
10	Non-target progression--the fine line between objectivity and subjectivity. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 3271-2	7.5
9	DNA Repair Defects for Therapy in Ovarian Cancer: The BRCA1/2 and PARP Inhibitor Story. <i>Indian Journal of Gynecologic Oncology</i> , <b>2017</b> , 15, 65-75	0.2
8	PEGylated liposomal doxorubicin: present and future role in the treatment of ovarian cancer. <i>Expert Review of Obstetrics and Gynecology</i> , <b>2008</b> , 3, 21-31	
7	Epithelial Ovarian Cancer <b>2015</b> , 419-429	
6	Quality assurance metrics in clinical trial conduct.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 274-274	2.2
5	Prognostic effects of clinical and tumor (t) factors in bevacizumab (BEV)-treated patients (pts) with ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5556-5556	2.2
4	Adjuvant treatment in early stage cervical cancer-does more equal better?. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1467-1468	3.5
3	Can variant negative be high-grade serous ovarian carcinoma? A case series. <i>Gynecologic Oncology Reports</i> , <b>2021</b> , 36, 100729	1.3
2	The role of cediranib in ovarian cancer: current status and further investigation. <i>Expert Opinion on Orphan Drugs</i> , <b>2016</b> , 4, 855-865	1.1
1	With Our Powers Combined: Exploring PARP Inhibitors and Immunotherapy.. <i>Cancer Journal (Sudbury, Mass )</i> , <b>2021</b> , 27, 511-520	2.2